Global Information
회사소개 | 문의 | 위시리스트

페닐케톤뇨증 파이프라인 의약품 : 기회 평가, 역학 연구, 시장 역학, 파이프라인 분석

Phenylketonuria Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H2 2019

리서치사 GervanoRA Data Services LLP
발행일 2020년 01월 상품 코드 923033
페이지 정보 영문 149 Pages
가격
US $ 2,500 ₩ 3,044,000 PDF by E-mail (General License)


페닐케톤뇨증 파이프라인 의약품 : 기회 평가, 역학 연구, 시장 역학, 파이프라인 분석 Phenylketonuria Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H2 2019
발행일 : 2020년 01월 페이지 정보 : 영문 149 Pages

세계의 페닐케톤뇨증 치료제(Phenylketonuria Drugs) 시장에 대해 조사 분석했으며, 개발 단계별 파이프라인 분자, 미충족 요구와 기회, 시장 역학, 특허 분석, 파이프라인 분석, 임상 단계·전임상 단계의 개발약 설명, 기회 평가, 현재 및 향후의 경쟁 상황, 기업 분석 등 체계적인 정보를 제공합니다.

목차

제1장 서론

제2장 주요 요약

제3장 질환 개요

  • 질환 정의와 증상
  • 병인과 분류
  • 질환 진단
  • 치료 알고리즘과 가이드라인
  • 역학 연구
  • 역학 예측

제4장 페닐케톤뇨증 경쟁 분야의 시장 역학

  • 거래(M&A/제휴)
  • 특허 분석(만료, 제네릭 의약품)

제5장 페닐케톤뇨증의 파이프라인 의약품 분석

  • 파이프라인 의약품 분석 : 개발 단계별
  • 파이프라인 의약품 분석 : 지역별
  • 파이프라인 의약품 분석 : 투여 경로별
  • 파이프라인 의약품 분석 : 약제 분류별
  • 파이프라인 의약품 분석 : 작용기서별
  • 파이프라인 의약품 분석 : 대학·기관별

제6장 파이프라인 의약품의 설명과 개발 마일스톤

  • 단계 2 개발약의 설명과 개발 마일스톤
  • 단계 1 개발약의 설명과 개발 마일스톤
  • 전임상 단계 개발약의 설명과 개발 마일스톤

제7장 페닐케톤뇨증 파이프라인 의약품의 추정 승인 스케줄

  • 방법
  • 미국과 미국 이외의 추정 승인 스케줄

제8장 임상시험 개요

  • 애널리틱스 : 임상시험 결과별
  • 진행중인 임상시험 개요
  • 최근 완료한 임상시험 개요
  • 계획중인 임상시험 개요
  • 중지·종료한 임상시험

제9장 경쟁 벤치마킹에 의한 기회 평가

  • 외부의 의존
  • 파이프라인 포트폴리오
  • 기대되는 시장 진출
  • 특허와 배타성
  • 제휴 활동을 수반하는 시장 역학
  • 특별한 규제 허가의 달성
  • 기업의 발전

제10장 기업 개요에 의한 현재 및 향후의 경쟁 상황 평가

  • 기존 기업
  • 신흥 기업

제11장 약어

KSM 20.02.13

GervanoRA's pipeline analysis and opportunity assessment report "Phenylketonuria Pipeline Drugs - Opportunity Assessments, Market Dynamics and Pipeline Analytics H2 2019" analyzed and assessed Phenylketonuria (PKU) pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Phenylketonuria drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Phenylketonuria area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Phenylketonuria drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, and Pipeline Analytics by Company Type. The report has also highlighted the universities and institutes working on the development of new innovative therapeutics for the treatment of Phenylketonuria.

Our comprehensive analysis on the Phenylketonuria drug pipeline identified twenty-one (21) drug candidates undergoing different stages of development- from Early R&D to Phase 2 stage. Among these, five drug candidates are in clinical stages of development and a total of sixteen molecules are in non-clinical stage of development. The drug pipeline consists of thirteen preclinical drug candidates and three still in their early stages of discovery.

The report has covered a total of nineteen (19) companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 12 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of all Clinical Stage Pipeline Drug Candidates
  • Clinical Stage and Preclinical Stage Drug Descriptions along with Development Milestones
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Key Established Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE PHENYLKETONURIA COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

3. DISEASE OVERVIEW

  • 3.1 DISEASE DEFINITION AND SYMPTOMS
  • 3.2 DISEASE CAUSE AND CLASSIFICATION
  • 3.3 DISEASE DIAGNOSIS
  • 3.4 TREATMENT ALGORITHM AND GUIDELINES
  • 3.5 EPIDEMIOLOGY STUDIES
    • 3.5.1. GLOBAL AND HISTORICAL TRENDS
  • 3.6 EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET DYNAMICS OF PHENYLKETONURIA DISEASE COMPETITIVE SPACE

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    • 4.1.1 MERGERS AND ACQUISITIONS
    • 4.1.2. COLLABORATION AGREEMENTS
    • 4.1.3. LICENSING AGREEMENTS
    • 4.1.4. FINANCING DEALS
    • 4.1.5. TERMINATION AGREEMENTS AND SETTLEMENTS
  • 4.2. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    • 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

5. PIPELINE DRUGS ANALYTICS OF PHENYLKETONURIA DISEASE

  • 5.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 5.1.1. CLINICAL STAGE DRUG CANDIDATES
    • 5.1.2. PRECLINICAL STAGE DRUG CANDIDATES
    • 5.1.3. EARLY R&D STAGE DRUG CANDIDATES
  • 5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • 5.7. PIPELINE DRUGS ANALYTICS BY UNIVERSITIES AND INSTITUTES - LICENSING OPPORTUNITIES

6. PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 6.1. PHASE 2 STAGE OF DEVELOPMENT DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • CNSA-001 (Sepiapterin) - (Censa Pharmaceuticals Inc)
    • HMI-102 Gene Therapy - (Homology Medicines Inc)
    • SYNB1618 - (Synlogic Inc)
  • 6.2. PHASE 1 STAGE OF DEVELOPMENT DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • CDX-6114 - (Codexis, Inc/Nestle Health Science)
    • RTX-134 - (Rubius Therapeutics Inc)
  • 6.3. PRECLINICAL STAGE OF DEVELOPMENT DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • BMN-307 - (BioMarin Pharmaceutical Inc)
    • ST-101 - (Sangamo Therapeutics)
    • mRNA-3283 - (Moderna Therapeutics Inc)
    • Gene Therapy - (Generation Bio Corp)
    • HMI-103 Gene Editing - (Homology Medicines Inc)
    • SOM1311 - (SOM Innovation Biotech SL)
    • Lentivirus (LV) Gene Therapy - (American Gene Technologies International Inc)
    • Phelimin - (MipSalus ApS)
    • UX501 - (Ultragenyx Pharmaceutical)
    • Metabolic Target - (Agios Pharmaceuticals Inc)
    • ERYZYME - (Erytech Pharma SA)
    • Ery-PAL - (EryDel SpA)
    • CRISPR-Cas Based Genome Editing Therapy - (Beam Therapeutics)

7. ESTIMATED APPROVAL TIMELINES OF PHENYLKETONURIA PIPELINE DRUGS

  • 7.1. METHODOLOGY
  • 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

8. CLINICAL TRIALS SUMMARY

  • 8.1. ANALYTICS BY CLINICAL TRIAL RESULTS
    • 8.1.1. KEY PHASE 2 CLINICAL TRIAL RESULTS
    • 8.1.2. KEY PHASE 1 CLINICAL TRIAL RESULTS
  • 8.2. ONGOING CLINICAL TRIALS SUMMARY
    • 8.2.1. PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    • 8.2.2. PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
  • 8.3. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    • 8.3.1. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
    • 8.3.2. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
  • 8.4. PLANNED CLINICAL TRIALS SUMMARY
  • 8.5. WITHDRAWN AND TERMINATED CLINICAL TRIALS

9. OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

  • 9.1. EXTERNAL DEPENDENCIES
  • 9.2. PIPELINE PORTFOLIO
  • 9.3. EXPECTED MARKET ENTRIES
  • 9.4. PATENTS AND EXCLUSIVITY
  • 9.5. MARKET DYNAMICS WITH PARTNERING ACTIVITIES
  • 9.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 9.7. COMPANY DEVELOPMENTS

10. ASSESSMENT OF CURRENT AND FUTURE COMPETITIVE LANDSCAPE THROUGH COMPANY PROFILES

  • 10.1. ESTABLISHED COMPANIES
    • 10.1.1. KEY ESTABLISHED COMPANY PROFILES AND SWOT ANALYSIS
      • 10.1.1.1. BIOMARIN PHARMACEUTICAL INC
  • 10.2. EMERGING COMPANIES
    • 10.2.1. KEY EMERGING COMPANY PROFILES
      • 10.2.1.1: TRUCODE GENE REPAIR INC
      • 10.2.1.2: CENSA PHARMACEUTICALS INC
      • 10.2.1.3: HOMOLOGY MEDICINES INC
      • 10.2.1.4: RUBIUS THERAPEUTICS INC
      • 10.2.1.5: SYNLOGIC INC
      • 10.2.1.6: AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC
      • 10.2.1.7: ERYDEL SPA
      • 10.2.1.8: GENERATION BIO CO
      • 10.2.1.9: MIPSALUS APS
      • 10.2.1.10: MODERNA THERAPEUTICS INC
      • 10.2.1.11: SANGAMO THERAPEUTICS INC
      • 10.2.1.12: SOM INNOVATION BIOTECH SL

11. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: PHENYLKETONURIA REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: MAJOR MERGERS AND ACQUISITION DEALS IN PHENYLKETONURIA DISEASE AREA
  • TABLE 03: MAJOR COLLABORATION DEALS IN PHENYLKETONURIA DISEASE AREA
  • TABLE 04: MAJOR LICENSING DEALS IN PHENYLKETONURIA DISEASE AREA
  • TABLE 05: MAJOR FINANCING DEALS IN PHENYLKETONURIA DISEASE AREA
  • TABLE 06: MAJOR TERMINATION DEALS IN PHENYLKETONURIA DISEASE AREA
  • TABLE 07: LIST OF PATENTS AND PATENT APPLICATIONS OF CENSA PHARMACEUTICALS
  • TABLE 08: LIST OF PATENTS AND PATENT APPLICATIONS OF AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC
  • TABLE 09: INTERNATIONAL PATENT APPLICATIONS OF MIPSALUS
  • TABLE 10: U.S PATENTS AND PATENT APPLICATIONS OF MIPSALUS
  • TABLE 11: U.S PATENTS AND PATENT APPLICATIONS PATENTS OF GENERATION BIO
  • TABLE 12: PKU PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 13: CLINICAL STAGE DRUG CANDIDATES FOR PHENYLKETONURIA
  • TABLE 14: PRECLINICAL STAGE DRUG CANDIDATES FOR PHENYLKETONURIA
  • TABLE 15: PHENYLKETONURIA PIPELINE ANALYTICS BY INJECTABLE AS ROA
  • TABLE 16: PHENYLKETONURIA PIPELINE ANALYTICS BY DRUG CLASSES
  • TABLE 17: PHENYLKETONURIA PIPELINE ANALYTICS BY COMPANY TYPE
  • TABLE 18: PHENYLKETONURIA PIPELINE DRUGS BY UNIVERSITIES AND INSTITUTES
  • TABLE 19: ESTIMATED APPROVAL TIMELINE OF ALL CLINICAL STAGE DRUGS FOR PHENYLKETONURIA
  • TABLE 20: DOSE LEVELS OF CNSA-001
  • TABLE 21: STUDY DESIGN OF HMI-102 BY HOMOLOGY MEDICINES
  • TABLE 22: ONGOING PHASE 1 CLINICAL TRIALS FOR PHENYLKETONURIA
  • TABLE 23: STUDY DESIGN OF RTX-134 BY RUBIUS THERAPEUTICS
  • TABLE 24: STUDY DESIGN OF CDX-6114 BY NESTLE
  • TABLE 25: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS FOR PHENYLKETONURIA
  • TABLE 26: BIOMARIN PHARMACEUTICAL'S RAVPAL-PEG STUDY DESIGN
  • TABLE 27: STUDY DESIGN OF PHASE 2 TRIAL OF KUVAN BY UNIVERSITY OF MIAMI
  • TABLE 28: STUDY DESIGN OF PHASE 2 TRIAL OF CNSA-001 BY CENSA PHARMACEUTICALS
  • TABLE 29: STUDY DESIGN OF PHASE 1 TRIAL OF SYNB1618 BY SYNLOGIC
  • TABLE 30: TERMINATED TRIALS OF PHENYLKETONURIA DRUGS
  • TABLE 31: LIST OF PATENTS AND PATENT APPLICATIONS OF CENSA PHARMACEUTICALS
  • TABLE 32: LIST OF PATENTS AND PATENT APPLICATIONS OF AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC
  • TABLE 33: INTERNATIONAL PATENT APPLICATIONS OF MIPSALUS
  • TABLE 34: U.S PATENTS AND PATENT APPLICATIONS PATENTS OF MIPSALUS
  • TABLE 35: U.S PATENTS AND PATENT APPLICATIONS PATENTS OF GENERATION BIO
  • TABLE 36: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • TABLE 37: MAJOR PRODUCTS OF BIOMARIN
  • TABLE 38: UNDER DEVELOPMENT PRODUCT PIPELINE OF BIOMARIN
  • TABLE 39: ANTICIPATED MILESTONES OF BIOMARIN IN THE YEAR OF 2020
  • TABLE 40: RESEARCH AND DEVELOPMENT ACTIVITIES OF BIOMARIN
  • TABLE 41: RECENT DEVELOPMENTS OF BIOMARIN
  • TABLE 42: PRESENTATIONS AND EVENTS OF BIOMARIN
  • TABLE 43: TRUCODE GENE REPAIR PIPELINE ASSETS
  • TABLE 44: PATENT APPLICATIONS OF TRUCODE GENE REPAIR
  • TABLE 45: PUBLICATIONS OF TRUCODE GENE REPAIR
  • TABLE 46: CENSA PHARMACEUTICALS PIPELINE ASSETS
  • TABLE 47: LIST OF PATENTS AND PATENT APPLICATIONS OF CENSA PHARMACEUTICALS
  • TABLE 48: R&DACTIVITIES AND RECENT DEVELOPMENTS OF CENSA PHARMACEUTICALS
  • TABLE 49: HOMOLOGY GENETIC MEDICINES PIPELINE ASSETS
  • TABLE 50: ANTICIPATED MILESTONES OF HOMOLOGY
  • TABLE 51: RESEARCH AND DEVELOPMENT ACTIVITIES OF HOMOLOGY
  • TABLE 52: RECENT DEVELOPMENTS OF HOMOLOGY
  • TABLE 53: PRESENTATIONS AND EVENTS OF HOMOLOGY
  • TABLE 54: RUBIUS PIPELINE ASSETS
  • TABLE 55: ANTICIPATED NEAR FUTURE MILESTONES OF RUBIUS
  • TABLE 56: DESEASE RELATED PATENTS OF RUBIUS
  • TABLE 57: RARE DESEASE RELATED PATENTS OF RUBIUS
  • TABLE 58: RESEARCH AND DEVELOPMENT ACTIVITIES OF RUBIUS
  • TABLE 59: RECENT DEVELOPMENTS OF RUBIUS
  • TABLE 60: PRESENTATIONS AND EVENTS OF RUBIUS
  • TABLE 61: SYNLOGIC PIPELINE ASSETS
  • TABLE 62: ANTICIPATED MILESTONES OF SYNLOGIC
  • TABLE 63: RESEARCH AND DEVELOPMENT ACTIVITIES OF SYNLOGIC
  • TABLE 64: RECENT DEVELOPMENTS OF SYNLOGIC
  • TABLE 65: PRESENTATIONS AND EVENTS OF SYNLOGIC
  • TABLE 66: AMERICAN GENE TECHNOLOGIES PIPELINE ASSETS
  • TABLE 67: PATENTS OF AMERICAN GENE TECHNOLOGIES
  • TABLE 68: RESEARCH AND DEVELOPMENT ACTIVITIES OF AMERICAN GENE TECHNOLOGIES
  • TABLE 69: RECENT DEVELOPMENTS OF AMERICAN GENE TECHNOLOGIES
  • TABLE 70: PUBLICATIONS OF AMERICAN GENE TECHNOLOGIES
  • TABLE 71: PIPELINE ASSETS OF ERYDEL
  • TABLE 72: PATENTS OF ERYDEL
  • TABLE 73: RESEARCH AND DEVELOPMENT ACTIVITIES OF ERYDEL
  • TABLE 74: RECENT DEVELOPMENTS OF ERYDEL
  • TABLE 75: GENERATION BIO PIPELINE ASSETS
  • TABLE 76: U.S PATENTS AND PATENT APPLICATIONS PATENTS OF GENERATION BIO
  • TABLE 77: RECENT DEVELOPMENTS OF GENERATION BIO
  • TABLE 78: PRESENTATIONS OF GENERATION BIO
  • TABLE 79: INTERNATIONAL PATENT APPLICATIONS OF MIPSALUS
  • TABLE 80: U.S PATENTS AND PATENT APPLICATIONS PATENTS OF MIPSALUS
  • TABLE 81: RESEARCH AND DEVELOPMENT ACTIVITIES OF MIPSALUS
  • TABLE 82: RECENT DEVELOPMENTS OF MIPSALUS
  • TABLE 83: PRESENTATIONS AND EVENTS OF MIPSALUS
  • TABLE 84: PIPELINE ASSETS OF MODERNA THERAPEUTICS WITH RESPECT TO PROPHYLACTIC VACCINES
  • TABLE 85: PIPELINE ASSETS OF MODERNA THERAPEUTICS WITH RESPECT TO CANCER VACCINES
  • TABLE 86: PIPELINE ASSETS OF MODERNA THERAPEUTICS WITH RESPECT TO INTRATUMORAL IMMUNO-ONCOLOGY
  • TABLE 87: PIPELINE ASSETS OF MODERNA THERAPEUTICS WRT SYSTEMIC SECRETED AND CELL SURFACE THERAPEUTICS
  • TABLE 88: PIPELINE ASSETS OF MODERNA THERAPEUTICS WITH RESPECT TO SYSTEMIC INTRACELLULAR THERAPEUTICS
  • TABLE 89: RESEARCH AND DEVELOPMENT ACTIVITIES OF MODERNA
  • TABLE 90: RECENT DEVELOPMENTS OF MODERNA
  • TABLE 91: PRESENTATION AND EVENTS OF MODERNA
  • TABLE 92: SANGAMO'S PIPELINE ASSETS
  • TABLE 93: ANTICIPATED NEAR FUTURE MILESTONES OF SANGAMO
  • TABLE 94: SANGAMO'S PATENT PORTFOLIO
  • TABLE 95: RESEARCH AND DEVELOPMENT ACTIVITIES OF SANGAMO
  • TABLE 96: RECENT DEVELOPMENTS OF SANGAMO
  • TABLE 97: PRESENTATIONS AND EVENTS OF SANGAMO
  • TABLE 98: SOM'S PRODUCT PIPELINE
  • TABLE 99: SOM'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 100: SOM'S RECENT DEVELOPMENTS
  • TABLE 101: SOM'S PRESENTATIONS AND EVENTS

LIST OF FIGURES

  • FIGURE 01: KEY EVENTS IN THE PHENYLKETONURIA COMPETITIVE SPACE
  • FIGURE 02: PHENYLKETONURIA DEALS SCENARIO
  • FIGURE 03: PKU PIPELINE DRUGS WRT STAGES OF DEVELOPMENT
  • FIGURE 04: PHENYLKETONURIA PIPELINE ANALYTICS BY COMPANY TYPE
  • FIGURE 05: RESEARCH AND DEVELOPMENT EXPENSES OF TOP 5 COMPANIES IN $M
  • FIGURE 06: PIPELINE PORTFOLIO OF COMPANIES WITH (NUMBER OF MOLECULES)
  • FIGURE 07: EXPECTED MARKET ENTRY WITH RESPECT TO DRUG CANDIDATES TREATING PHENYLKETONURIA
  • FIGURE 08: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO PHENYLKETONURIA TREATMENTS
  • FIGURE 09: RANKING TOP 5 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 10: R&D EXPENSES AS WELL AS NET PRODUCT REVENUES FOR YEARS 2016, 2017 AND 2018 OF BIOMARIN
  • FIGURE 11: PRODUCT REVENUES AND R&D EXPENSES FOR THE FIRST NINE MONTHS OF 2018 AND 2019
  • FIGURE 12: SALES BREAK DOWN BASED ON PRODUCTS (LEFT) AND GEOGRAPHIES (RIGHT)
  • FIGURE 13: R&D EXPENSES OF HOMOLOGY IN $M FOR THE THREE MONTHS ENDED SEPTEMBER 30 (2018 AND 2019)
  • FIGURE 14: R&D EXPENSES OF RUBIUS IN $M FOR THREE MONTHS ENDED SEPTEMBER 30 (2018 AND 2019)
  • FIGURE 15: R&D EXPENSES OF SYNLOGIC IN $M FOR THE THREE MONTHS ENDED SEPTEMBER 30(2018 AND 2019)
  • FIGURE 16: R&D EXPENSES AND TOTAL NET REVNUES FOR THE FINANCIAL YEARS OF 2016, 2017 AND 2018 IN $M
  • FIGURE 17: TOTAL R&D EXPENSES OF SANGAMO (2016, 2017, 2018) IN $
  • FIGURE 18: TOTAL R&D EXPENSES OF SANGAMO FOR THE FIRST NINE MONTHS OF 2019 IN THOUSAND
Back to Top
전화 문의
F A Q